Effect of Nebivolol on MIBG Parameters and Exercise in Heart Failure with Normal Ejection Fraction
- PMID: 27096522
- PMCID: PMC4914000
- DOI: 10.5935/abc.20160046
Effect of Nebivolol on MIBG Parameters and Exercise in Heart Failure with Normal Ejection Fraction
Abstract
Background: More than 50% of the patients with heart failure have normal ejection fraction (HFNEF). Iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy and cardiopulmonary exercise test (CPET) are prognostic markers in HFNEF. Nebivolol is a beta-blocker with vasodilating properties.
Objectives: To evaluate the impact of nebivolol therapy on CPET and123I-MIBG scintigraphic parameters in patients with HFNEF.
Methods: Twenty-five patients underwent 123I-MIBG scintigraphy to determine the washout rate and early and late heart-to-mediastinum ratios. During the CPET, we analyzed the systolic blood pressure (SBP) response, heart rate (HR) during effort and recovery (HRR), and oxygen uptake (VO2). After the initial evaluation, we divided our cohort into control and intervention groups. We then started nebivolol and repeated the tests after 3 months.
Results: After treatment, the intervention group showed improvement in rest SBP (149 mmHg [143.5-171 mmHg] versus 135 mmHg [125-151 mmHg, p = 0.016]), rest HR (78 bpm [65.5-84 bpm] versus 64.5 bpm [57.5-75.5 bpm, p = 0.028]), peak SBP (235 mmHg [216.5-249 mmHg] versus 198 mmHg [191-220.5 mmHg], p = 0.001), peak HR (124.5 bpm [115-142 bpm] versus 115 bpm [103.7-124 bpm], p= 0.043), HRR on the 1st minute (6.5 bpm [4.75-12.75 bpm] versus 14.5 bpm [6.7-22 bpm], p = 0.025) and HRR on the 2nd minute (15.5 bpm [13-21.75 bpm] versus 23.5 bpm [16-31.7 bpm], p = 0.005), but no change in peak VO2 and 123I-MIBG scintigraphic parameters.
Conclusion: Despite a better control in SBP, HR during rest and exercise, and improvement in HRR, nebivolol failed to show a positive effect on peak VO2 and 123I-MIBG scintigraphic parameters. The lack of effect on adrenergic activity may be the cause of the lack of effect on functional capacity.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures


Similar articles
-
Relationship between cardiac adrenergic image and exercise testing in heart failure.Arq Bras Cardiol. 2011 May;96(5):370-5. doi: 10.1590/s0066-782x2011005000044. Epub 2011 Apr 15. Arq Bras Cardiol. 2011. PMID: 21503390 English, Portuguese, Spanish.
-
Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis.J Am Coll Cardiol. 1999 Mar;33(3):759-66. doi: 10.1016/s0735-1097(98)00608-1. J Am Coll Cardiol. 1999. PMID: 10080478
-
Is abnormal adrenergic activation associated with abnormal Heart Rate Recovery?Arq Bras Cardiol. 2012 May;98(5):398-405. doi: 10.1590/s0066-782x2012005000027. Epub 2012 Mar 27. Arq Bras Cardiol. 2012. PMID: 22450335 English, Portuguese.
-
Do interleukin-1β levels correlate with MIBG and exercise parameters in heart failure?Arq Bras Cardiol. 2013 May;100(5):395-403. doi: 10.5935/abc.20130056. Epub 2013 Apr 9. Arq Bras Cardiol. 2013. PMID: 23568097 English, Portuguese.
-
Cardiac sympathetic nervous disintegrity is related to exercise intolerance in patients with chronic heart failure.Nucl Med Commun. 1998 May;19(5):451-6. doi: 10.1097/00006231-199805000-00007. Nucl Med Commun. 1998. PMID: 9853334 Clinical Trial.
Cited by
-
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.Cochrane Database Syst Rev. 2021 May 22;5(5):CD012721. doi: 10.1002/14651858.CD012721.pub3. Cochrane Database Syst Rev. 2021. PMID: 34022072 Free PMC article.
-
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.Cochrane Database Syst Rev. 2018 Jun 28;6(6):CD012721. doi: 10.1002/14651858.CD012721.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2021 May 22;5:CD012721. doi: 10.1002/14651858.CD012721.pub3. PMID: 29952095 Free PMC article. Updated.
References
-
- Edelmann F, Gelbrich G, Duvinage A, Stahrenberg R, Behrens A, Prettin C, et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction: results of the Aldo-DHF Trial. Int J Cardiol. 2013;169(6):408–417. - PubMed
-
- Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539–2550. - PubMed
-
- Kindermann M, Reil JC, Pieske B, van Veldhuisen DJ, Bohm M. Heart failure with normal left ventricular ejection fraction: what is the evidence? Trends Cardiovasc Med. 2008;18(8):280–292. - PubMed
-
- Munzel T, Gori T. Nebivolol. The somewhat-different β-adrnergic receptor blocker. J AM Coll Cardiol. 2009;54(16):1491–1499. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical